Management and prevention of Neisseria meningitidis and Neisseria gonorrhoeae infections in the context of evolving antimicrobial resistance trends
Open Access
- 27 November 2024
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (2) , 233-250
Abstract
Purpose: To describe the relationships between Neisseria meningitidis (NM) and Neisseria gonorrhoeae (NG) at genetic, population, and individual levels; to review historical trends in antimicrobial resistance (AMR); to review the treatment and preventive landscapes and explore their potential impact on AMR. Methods: A narrative literature search was conducted in PubMed, with searches restricted to 2003–2023 and additional articles included based on expertise. Results: NM and NG are closely related bacterial pathogens causing invasive meningococcal disease (IMD) and gonorrhea, respectively. NM can currently be treated with most antibiotics and generally has a wild-type susceptibility profile, whereas NG is increasingly resistant even in the first line of treatment. These pathogens share 80–90% genetic identity and can asymptomatically cohabit the pharynx. While AMR has historically been rare for NM, recent reports show this to be an emerging clinical concern. Extensively drug-resistant NG are reported globally, with data available from 73 countries, and can lead to treatment failure. Importantly, Neisseria commensals within the normal microbiota in the pharynx can act as a genetic reservoir of resistance to extended-spectrum cephalosporins. Novel oral antibiotics are urgently needed to treat a growing threat from antibiotic-resistant NG, recognized as a major global concern to public health by the World Health Organization. Numerous vaccines are available to prevent IMD, but none are approved for gonorrhea. Research to identify suitable candidates is ongoing. Conclusion: Holistic management of AMR in IMD and gonorrhea should couple judicious use of existing antibiotics, optimization of vaccination programs, and development of novel antibiotics and vaccines. GraphicalKeywords
This publication has 156 references indexed in Scilit:
- Type IIA topoisomerase inhibition by a new class of antibacterial agentsNature, 2010
- Prevalence and antimicrobial resistance pattern of bacterial meningitis in EgyptAnnals of Clinical Microbiology and Antimicrobials, 2009
- Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-ResistantStreptococcus pneumoniaeNew England Journal of Medicine, 2006
- Meningococcal disease: History, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and preventionIndian Journal of Medical Microbiology, 2006
- Comparative Genomics Identifies the Genetic Islands That Distinguish Neisseria meningitidis , the Agent of Cerebrospinal Meningitis, from Other Neisseria SpeciesInfection and Immunity, 2002
- High-Level Chloramphenicol Resistance inNeisseria meningitidisNew England Journal of Medicine, 1998
- Analysis of the genetic differences between Neisseria meningitidis and Neisseria gonorrhoeae: two closely related bacteria expressing two different pathogenicities.Proceedings of the National Academy of Sciences, 1996
- Interspecies recombination between the penA genes of Neisseria meningitidis and commensal Neisseria species during the emergence of penicillin resistance in N. meningitidis: natural events and laboratory simulationJournal of Bacteriology, 1994
- SPREAD OF PENICILLINASE-PRODUCING AND TRANSFER PLASMIDS FROM THE GONOCOCCUS TO NEISSERIA MENINGITIDISThe Lancet, 1983
- Epidemiological patterns of meningococcal disease in Norway 1975-1979.1980